Systemic sclerosis & Raynaud's
Neutrophil-to-lymphocyte ratio as a biomarker for clinical response after autologous haematopoietic stem cell transplantation in systemic sclerosis
Authors' conclusion
NLR is a simple biomarker that correlated with outcome measures in SSc following AHSCT but not with conventional therapy or CAR-T therapy.
Study context
- Population
- Patients with progressive diffuse SSc
- Exposure
- AHSCT vs rituximab plus MMF vs CAR-T therapy, with healthy controls
- AHSCTn = 15
- Combinationn = 15
- CAR-Tn = 6
- Outcome
- NLR changes as a biomarker for treatment response
- Follow-up
- 2 years
Methodological detailslinear mixed model, 2-year follow-up
- Linear mixed model
- 2-year follow-up
Main finding
As reported in the abstract
NLR change over time · up to 24 months
- Neutrophil-to-lymphocyte ratio (NLR) increased above 3 in two patients who relapsed after AHSCT
- 2
Observational data: associations, not effects.
Further findings
Baseline mean NLR
- Baseline mean NLR high (>2.95) in AHSCT, combination and CAR-T vs HC
Modified Rodnan Skin Score (mRSS) and forced vital capacity (FVC)% predicted · up to 12 months
- All treatment arms showed a significant decrease in mRSS and an increase in FVC% at each time point up to 12 months
Original publication
Neutrophil-to-lymphocyte ratio as a biomarker for clinical response after autologous haematopoietic stem cell transplantation in systemic sclerosis. Rheumatology (Oxford). Published 1 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →